AtaiBeckley
biotech · pharma · mental health
Eli Lilly to acquire AtaiBeckley for $2.8B in psychedelic depression bet
July 16, 2026
The deal shows major drugmakers now see psychedelic compounds as a legitimate new class for treatment-resistant depression.
Lead Investors
Eli Lilly
Read the Full Story in Velocity
Get curated startup and tech news with new stories published daily, company insights, and real-time alerts.